1. Pediatric randomized trial EORTC CLG 58951: Outcome for adolescent population with acute lymphoblastic leukemia
- Author
-
Yves Bertrand, Pierre-Simon Rohrlich, Laura Olivier-Gougenheim, Hélène Cavé, Barbara De Moerloose, Anne Uyttebroeck, Alina Ferster, Stefan Suciu, Carine Domenech, Chloé Arfeuille, Geneviève Plat, N Sirvent, Hospices Civils de Lyon (HCL), AP-HP Hôpital universitaire Robert-Debré [Paris], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), European Organization for Research and Treatment of Cancer (EORTC), EORTC, Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier), Université de Montpellier (UM), CHU Toulouse [Toulouse], Hôpital Universitaire des Enfants Reine Fabiola [Bruxelles, Belgique] (HUDERF), Universiteit Gent = Ghent University [Belgium] (UGENT), University Hospitals Leuven [Leuven], and Centre Hospitalier Universitaire de Nice (CHU Nice)
- Subjects
Male ,Cancer Research ,Pediatrics ,MESH: Remission Induction ,MESH: Combined Modality Therapy ,Lymphoblastic Leukemia ,genetic abnormalities ,law.invention ,chemistry.chemical_compound ,0302 clinical medicine ,Randomized controlled trial ,law ,Antineoplastic Combined Chemotherapy Protocols ,Medicine ,Young adult ,MESH: Treatment Outcome ,education.field_of_study ,Remission Induction ,Hematopoietic Stem Cell Transplantation ,clinical trial ,[SDV.MHEP.HEM]Life Sciences [q-bio]/Human health and pathology/Hematology ,Hematology ,General Medicine ,Precursor Cell Lymphoblastic Leukemia-Lymphoma ,Prognosis ,Combined Modality Therapy ,3. Good health ,MESH: Antineoplastic Combined Chemotherapy Protocols ,MESH: Maintenance Chemotherapy ,Treatment Outcome ,Oncology ,030220 oncology & carcinogenesis ,outcome ,Female ,medicine.medical_specialty ,Asparaginase ,Population ,[SDV.CAN]Life Sciences [q-bio]/Cancer ,acute lymphoblastic leukemia ,MESH: Prognosis ,Maintenance Chemotherapy ,03 medical and health sciences ,Humans ,education ,MESH: Hematopoietic Stem Cell Transplantation ,MESH: Adolescent ,MESH: Precursor Cell Lymphoblastic Leukemia-Lymphoma ,MESH: Humans ,business.industry ,Cancer ,medicine.disease ,MESH: Male ,Adolescent population ,Clinical trial ,chemistry ,adolescent ,business ,MESH: Female ,030215 immunology - Abstract
International audience; Over the years, the prognosis of adolescents treated for acute lymphoblastic leukemia (ALL) has improved. However, this age group still represents a challenge with an overall survival (OS) of 60% compared to 85% in younger children. Herein, we report the outcome of adolescents treated in the European Organisation for Research and Treatment of Cancer (EORTC) 58951 clinical trial. EORTC 58951 clinical trial included patients with de novo ALL between 1998 and 2008. For this study, we analyzed data of all adolescents between 15 and under 18. Data from 97 adolescents were analyzed, 70 had B-lineage and 27 had T-lineage ALL. The 8-year event-free survival (EFS) and OS for the B-cell precursor ALL cases were 72.3% (59.4%-81.7%) and 80.8% (67.4%-89.1%), respectively. For the T-lineage, the 8-year EFS and OS were 57.4% (36.1%-74.0%) and 59.0% (36.1%-76.2%), respectively. "B-other" ALL, defined as BCP-ALL lacking any known recurrent genetic abnormalities were more frequent in our adolescent population (52.8%) than in younger children (27.1%). Outcome of adolescents in the EORTC 58951 study is supporting the findings that adolescents have better outcome in pediatric compared to adults' trials. Nevertheless, in pediatric studies, adolescents still have a worse prognosis than younger children. Despite the fact that specific unfavorable characteristics may be linked to the adolescent population, a careful study and characterization of adolescents "B-other" genetic abnormalities in ALL is critical to improve the outcome of this population.
- Published
- 2020
- Full Text
- View/download PDF